Healthcare Providers and Services
Company Overview of Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center is a cancer care hospital that engages in cancer prevention, treatment, research, and education. It offers a range of programs to help patients and families throughout various phases of treatment, including genetic counseling, rehabilitation, integrative medicine, counseling, pain and palliative care, cancer screening, and assistance in navigating life after treatment. The company provides childhood cancer treatments, including blood and marrow transplantation, pediatric surgery, and subspecialty services; and treatments for adolescents and young adults with various types of cancers. Its research areas include cancer biology and genetics, cell biology, ...
1275 York Avenue
New York, NY 10065
Founded in 1884
Key Executives for Memorial Sloan Kettering Cancer Center
Chief Executive Officer and President
Senior Vice President of Finance
Chief Investment Officer and Vice President
Chief Information Officer and Vice President of Information Systems
Compensation as of Fiscal Year 2016.
Memorial Sloan Kettering Cancer Center Key Developments
Juno Therapeutics Signs License Agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics
Aug 8 16
Juno Therapeutics has signed an exclusive license agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics. The contract has been signed for a novel fully-human binding domain targeting B-cell maturation antigen along with binding domains against two additional undisclosed multiple myeloma targets to be used for the potential development and commercialisation of chimeric antigen receptor cell therapies for patients with multiple myeloma. The binding domains were established under a collaboration contract between both firms. The parties expect the BCMA CAR to enter human testing as early as the first half of 2017. MSK and Eureka Therapeutics are eligible to receive an undisclosed upfront payment, additional payments upon the achievement of undisclosed clinical, regulatory, and commercial milestones, and royalties on net sales.
Medidata Collaborates with Memorial Sloan Kettering Cancer Center
Jul 19 16
Medidata announced it is collaborating with Memorial Sloan Kettering Cancer Center (MSK) to expand the use of mobile health (mHealth) technology in oncology treatment. Through the collaboration, Medidata and MSK will assess the viability of deploying wearable sensors and mobile technology to evaluate quality of life during cancer treatment. MSK will use activity trackers, mobile apps and Medidata’s cloud technology platform  to study patterns of movement in patients being treated for multiple myeloma.
National Brain Tumor Society Enters Partnership with Memorial Sloan Kettering
Jul 11 16
National Brain Tumor Society (NBTS) has entered into a Collaborative Agreement with Memorial Sloan Kettering Cancer Center (MSK) for the New York hospital and research institute to officially join its research program, the Defeat GBM Research Collaborative. The new agreement with MSK brings another institution into the Defeat GBM Research Collaborative as an official 'Scientific Collaborator' working toward the program's goals.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries